CONFERENCE COVERAGE 2023-05-05 Conference Coverage With the emergence of COVID-19 three years in the past, the lingering neurological effects after initial illness remain nebulous. At the recent International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg, Sweden, sci
RESEARCH NEWS 2023-05-05 Research News As anyone who’s tossed and turned through sleepless nights will know, chronic sleep deprivation can turn the simplest task into a challenge. Microglia, it turns out, suffer similarly from no shuteye. According to a study published April 26 i
RESEARCH NEWS 2023-05-04 Research News Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly press release. The treatment slowed decline
CONFERENCE COVERAGE 2023-05-03 Conference Coverage Tau pathology is proving a tough nut to crack, with most antibodies directed against it posting negative results in clinical trials thus far. At the recent International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg,
CONFERENCE COVERAGE 2023-05-02 Conference Coverage Do microglia thwart neurodegenerative disease, or help it along? Do they keep amyloid in check with one hand, while goading tau entanglement with the other? Do they protect neurons early on in disease, but sour into synaptic slayers la
CONFERENCE COVERAGE 2023-04-27 Conference Coverage After years of languishing in obscurity, the topic of disruptions in the brain's lipid metabolism is moving center stage. The number of publications in this area is growing, and at the International Conference on Alzheimer’s and P
RESEARCH NEWS 2023-04-26 Research News One strategy for targeting tau pathology—suppressing expression with an antisense oligonucleotide—has recently made strides. At AD/PD 2023, Biogen and partner Ionis Pharmaceuticals had reported that their tau antisense oligonucleotide BIIB08
CONFERENCE COVERAGE 2023-04-26 Conference Coverage Springing a leak is rarely good news, but when microglial mitochondria start oozing, it can be particularly bad in situations of tauopathy. So conclude scientists led by Li Gan and Sadaf Amin, Weill Cornell Medicine, New York, in the A
CONFERENCE COVERAGE 2023-04-25 Conference Coverage New data presented at the International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1 in Gothenburg, Sweden, further reinforced the field's growing recognition that microglia respond in myriad ways t
CONFERENCE COVERAGE 2023-04-25 Conference Coverage The scientific diet at this year’s International Conference on Alzheimer’s and Parkinson’s diseases, March 28 to April 1 in Gothenburg, was especially rich in news about the ins and outs of the microglial “gastrointestinal tract,” aka
CONFERENCE COVERAGE 2023-04-21 Conference Coverage Anti-amyloid immunotherapy has reached a milestone with the approval of two antibodies for clinical use; alas, the race is far from over. At the International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1
CONFERENCE COVERAGE 2023-04-21 Conference Coverage Seed amplification assays, those PCR-like reactions for toxic misfolded proteins, are starting to look pretty good. In the May Lancet Neurology, scientists led by Andrew Siderowf, University of Pennsylvania, Philadelphia, and Luis Conc
CONFERENCE COVERAGE 2023-04-20 Conference Coverage Retroviruses lurking in the human genome aren’t the only potential troublemakers in neurodegenerative diseases (see Part 5 of this series). Herpes simplex virus type 1 (HSV-1) integrates into the genome of trigeminal ganglia nerves, c
CONFERENCE COVERAGE 2023-04-18 Conference Coverage Signaling through the CD33 receptor counteracts the known beneficial microglial responses to plaques, while clusterin is thought to promote Aβ aggregation. Up until now, these two AD risk factors were thought to be going about their ne